{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:35:05Z","timestamp":1772447705499,"version":"3.50.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016916","name":"Royal Marsden Cancer Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016916","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020400","name":"John Black Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Patients with gastrointestinal (GI) cancers have an increased risk of serious complications and death from SARS-CoV-2 infection. The immunogenicity of vaccines in patients with GI cancers receiving anti-cancer therapies is unclear. We conducted a prospective study to evaluate the prevalence of neutralizing antibodies in a cohort of GI cancer patients receiving chemotherapy following SARS-CoV-2 vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Between September 2020 and April 2021, patients with cancer undergoing chemotherapy were enrolled. At baseline (day 0), days 28, 56, and 84, we assessed serum antibodies to SARS-CoV-2 spike (anti-S) and anti-nucleocapsid (anti-NP) and concomitantly assessed virus neutralization using a pseudovirus neutralization assay. Patients received either the Pfizer\/BioNTech BNT162b2, or the Oxford\/AstraZeneca ChAdOx1 vaccine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All 152 patients enrolled had a prior diagnosis of cancer; colorectal (n = 80, 52.6%), oesophagogastric (n = 38, 25.0%), and hepato pancreatic biliary (n = 22, 12.5%). Nearly all were receiving systemic anti-cancer therapy (99.3%). Of the 51 patients who did not receive a vaccination prior to, or during the study, 5 patients had detectable anti-NP antibodies. Ninety-nine patients received at least one dose of vaccine prior to, or during the study. Within 19 days following the first dose of vaccine, 30.0% had anti-S detected in serum which increased to 70.2% at days 20-39. In the 19 days following a second dose, anti-S positivity was 84.2% (32\/38). However, pseudovirus neutralization titers (pVNT80) decreased from days 20 to 39.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Despite the immunosuppressive effects of chemotherapy, 2 doses of SARS-CoV-2 vaccines are able to elicit a protective immune response in patients\u2019 ongoing treatment for gastrointestinal cancers. Decreases in pseudoviral neutralization were observed after 20-39 days, re-affirming the current recommendation for vaccine booster doses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trial Registration Number<\/jats:title>\n                  <jats:p>NCT04427280.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac230","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T16:58:44Z","timestamp":1665766724000},"page":"e1-e8","source":"Crossref","is-referenced-by-count":5,"title":["SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy"],"prefix":"10.1093","volume":"28","author":[{"given":"David K","family":"Lau","sequence":"first","affiliation":[{"name":"Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust , London and Surrey , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Aresu","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Development, Royal Marsden NHS Foundation Trust , London and Surrey , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Planche","sequence":"additional","affiliation":[{"name":"Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George\u2019s University of London , London , UK"},{"name":"St George\u2019s University Hospitals NHS Foundation Trust , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amina","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Development, Royal Marsden NHS Foundation Trust , London and Surrey , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Retchel","family":"Lazaro-Alcausi","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust , London and Surrey , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Duncan","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust , London and Surrey , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Kidd","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust , London and Surrey , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Cromarty","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust , London and Surrey , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruwaida","family":"Begum","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust , London and Surrey , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isma","family":"Rana","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust , London and Surrey , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su","family":"Li","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust , London and Surrey , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Abdulnabi","family":"Suwaidan","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust , London and Surrey , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Monahan","sequence":"additional","affiliation":[{"name":"Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George\u2019s University of London , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Clark","sequence":"additional","affiliation":[{"name":"Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George\u2019s University of London , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Eckersley","sequence":"additional","affiliation":[{"name":"Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George\u2019s University of London , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry M","family":"Staines","sequence":"additional","affiliation":[{"name":"Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George\u2019s University of London , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Groppelli","sequence":"additional","affiliation":[{"name":"Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George\u2019s University of London , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev","family":"Krishna","sequence":"additional","affiliation":[{"name":"Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George\u2019s University of London , London , UK"},{"name":"St George\u2019s University Hospitals NHS Foundation Trust , London , UK"},{"name":"Institut f\u00fcr Tropenmedizin, Universit\u00e4tsklinikum T\u00fcbingen , T\u00fcbingen , Germany"},{"name":"Centre de Recherches M\u00e9dicales de Lambar\u00e9n\u00e9 , Gabon , Lambar\u00e9n\u00e9"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Mayora-Neto","sequence":"additional","affiliation":[{"name":"Viral Pseudotype Unit (VPU Kent), Medway School of Pharmacy, University of Kent and Greenwich at Medway , Chatham Maritime, Kent , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7978-3815","authenticated-orcid":false,"given":"Nigel","family":"Temperton","sequence":"additional","affiliation":[{"name":"Viral Pseudotype Unit (VPU Kent), Medway School of Pharmacy, University of Kent and Greenwich at Medway , Chatham Maritime, Kent , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Fribbens","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust , London and Surrey , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Watkins","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust , London and Surrey , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1496-6792","authenticated-orcid":false,"given":"Naureen","family":"Starling","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust , London and Surrey , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0286-8703","authenticated-orcid":false,"given":"Ian","family":"Chau","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust , London and Surrey , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust , London and Surrey , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheela","family":"Rao","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Lymphoma Unit, Royal Marsden NHS Foundation Trust , London and Surrey , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"2023052314421957900_CIT0001"},{"issue":"3","key":"2023052314421957900_CIT0002","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"2023052314421957900_CIT0003","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamaoncol.2020.0980","article-title":"SARS-CoV-2 Transmission in patients with cancer at a tertiary care hospital in Wuhan, China","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10269","key":"2023052314421957900_CIT0004","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"27","key":"2023052314421957900_CIT0005","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2023052314421957900_CIT0006","author":"Department of Health and Social Care."},{"issue":"3","key":"2023052314421957900_CIT0007","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA"},{"issue":"8","key":"2023052314421957900_CIT0008","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2021.06.009","article-title":"Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer","volume":"39","author":"Addeo","year":"2021","journal-title":"Cancer Cell"},{"issue":"10","key":"2023052314421957900_CIT0009","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaoncol.2021.2675","article-title":"Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer","volume":"7","author":"Goshen-Lago","year":"2021","journal-title":"JAMA Oncol"},{"issue":"8","key":"2023052314421957900_CIT0010","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaoncol.2021.2155","article-title":"Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer","volume":"7","author":"Massarweh","year":"2021","journal-title":"JAMA Oncol"},{"issue":"21","key":"2023052314421957900_CIT0011","doi-asserted-by":"crossref","first-page":"e4236","DOI":"10.21769\/BioProtoc.4236","article-title":"Production, titration, neutralisation, storage and lyophilisation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) lentiviral pseudotypes","volume":"11","author":"Di Genova","year":"2021","journal-title":"Bio-protocol"},{"issue":"9","key":"2023052314421957900_CIT0012","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3390\/v12091011","article-title":"Characterisation of SARS-CoV-2 lentiviral pseudotypes and correlation between pseudotype-based neutralisation assays and live virus-based micro neutralisation assays","volume":"12","author":"Hyseni","year":"2020","journal-title":"Viruses"},{"issue":"42","key":"2023052314421957900_CIT0013","first-page":"2000685","article-title":"Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020","volume":"25","author":"Thompson","year":"2020","journal-title":"Euro Surveillance: Bull Eur sur les Maladies Transmiss = Eur Commun Dis Bull"},{"issue":"13","key":"2023052314421957900_CIT0014","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection","volume":"386","author":"Hall","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"2023052314421957900_CIT0015","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41591-022-01721-6","article-title":"Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines","volume":"28","author":"Wei","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"2023052314421957900_CIT0016","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"key":"2023052314421957900_CIT0017","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2021.10.013","article-title":"Evaluation of COVID-19 vaccine response in patients with cancer: an interim analysis","volume":"159","author":"Tran","year":"2021","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"8","key":"2023052314421957900_CIT0018","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"2023052314421957900_CIT0019","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.21.01891","article-title":"Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer: the CANVAX Cohort Study","volume":"40","author":"Naranbhai","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"2023052314421957900_CIT0020","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"issue":"6","key":"2023052314421957900_CIT0021","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3026(21)00110-1","article-title":"Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma","volume":"8","author":"Bird","year":"2021","journal-title":"Lancet Haematol"},{"key":"2023052314421957900_CIT0022","first-page":"2021.04.06.21254949","article-title":"Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients","author":"Agha","year":"2021","journal-title":"medRxiv: The Preprint Server Health Sci"},{"issue":"23","key":"2023052314421957900_CIT0023","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"issue":"26","key":"2023052314421957900_CIT0024","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/JCO.22.00088","article-title":"Humoral responses against SARS-CoV-2 and variants of concern after mRNA vaccines in patients with non-hodgkin lymphoma and chronic lymphocytic leukemia","volume":"40","author":"Chang","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"2023052314421957900_CIT0025","doi-asserted-by":"crossref","first-page":"e0009551","DOI":"10.1371\/journal.pntd.0009551","article-title":"Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: a systematic review and meta-analysis","volume":"15","author":"Savage","year":"2021","journal-title":"PLoS NeglTrop Dis"},{"key":"2023052314421957900_CIT0026","doi-asserted-by":"crossref","first-page":"108095","DOI":"10.1016\/j.intimp.2021.108095","article-title":"The WHO International Standard for COVID-19 serological tests: towards harmonization of anti-spike assays","volume":"100","author":"Infantino","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"2023052314421957900_CIT0027","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/S2666-5247(21)00266-4","article-title":"WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community","volume":"3","author":"Knezevic","year":"2022","journal-title":"Lancet Microbe"},{"issue":"8","key":"2023052314421957900_CIT0028","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.annonc.2021.04.019","article-title":"Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors","volume":"32","author":"Barri\u00e8re","year":"2021","journal-title":"Ann Oncol"},{"issue":"9","key":"2023052314421957900_CIT0029","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"issue":"3","key":"2023052314421957900_CIT0030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"issue":"3","key":"2023052314421957900_CIT0031","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"issue":"32","key":"2023052314421957900_CIT0032","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/1\/e1\/50423181\/oyac230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/1\/e1\/50423181\/oyac230.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T10:54:06Z","timestamp":1684839246000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/1\/e1\/6808328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,11,7]]},"published-print":{"date-parts":[[2023,1,18]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac230","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,11,7]]}}}